Adverse events after intravitreal infliximab (Remicade)

Retina

Volumn 30, Issue 1, 2010, Pages 71-80

  Giganti, Monica ^a,b   Beer, Paul M ^a,b   Lemanski, Nicole ^b   Hartman, Coby ^a,b   Schartman, Jerome ^a,b   Falk, Naomi ^a,b  

^a PLLC   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; BRIMONIDINE; CHIMERIC ANTIBODY; DORZOLAMIDE; INFLIXIMAB; PEGAPTANIB; PREDNISOLONE; PREDNISONE; RANIBIZUMAB; TIMOLOL; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ANGIOGRAPHY; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CENTRAL SEROUS RETINOPATHY; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DISEASE EXACERBATION; DRUG TOLERABILITY; EDEMA; ELECTRORETINOGRAPHY; ENDOPHTHALMITIS; EYE DISEASE; EYE REFRACTION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMMUNOGENICITY; INJECTION; INTERVENTION STUDY; INTRAOCULAR PRESSURE; LASER COAGULATION; LATENT PERIOD; LOW DRUG DOSE; MALE; OPTIC NERVE EDEMA; OPTICAL COHERENCE TOMOGRAPHY; PATIENT ASSESSMENT; PERIMETRY; PHOTODYNAMIC THERAPY; PILOT STUDY; PROSPECTIVE STUDY; RETINA; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINOTOXICITY; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; THICKNESS; TREATMENT FAILURE; UVEITIS; VISUAL ACUITY; VISUAL DISORDER; VITRITIS;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CHIMERA; CHOROIDAL NEOVASCULARIZATION; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR DEGENERATION; MACULAR EDEMA; MALE; MIDDLE AGED; PANUVEITIS; PERIMETRY; PILOT PROJECTS; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TUMOR NECROSIS FACTOR-ALPHA; VISUAL ACUITY; VITREOUS BODY;

EID: 75149190168     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181bcef3b     Document Type: Article

References (20)

1. Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol 2000;121:458-465.
2. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-1452.
3. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002;16:438-440.
4. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002;160:501-509.
5. Armstrong D, Augustin AJ, Spengler R, et al. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica 1998;212:410-414.
6. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1891-1898.
7. Guerrin M, Moukadiri H, Chollet P, et al. Vasculotropin/ vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995;164:385-394.
8. Busik JV, Mohr S, Grant MB. Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes 2008;57:1952-1965.
9. Yang P, McKay BS, Allen JB, Jaffe GJ. Effect of NF-kappa B inhibition on TNF-alpha-induced apoptosis in human RPE cells. Invest Ophthalmol Vis Sci 2004;45:2438-2446.
10. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004;138:648-650.
11. Sfikakis PP, Markomichelakis N, Theodossiadis GP, Grigoropoulos V, Katsilambros N, Theodossiadis PG. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005;28:445-447.
12. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol 2005;139:537-540.
13. Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol 2007;125:1221-1224.
14. Giansanti F, Ramazzotti M, Vannozzi L, et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 2008;49:1151-1156.
15. Theodossiadis PG, Liarakos VS, Sfikakis PP, et al. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol 2009; 247:273-281.
16. Ryan SJ, ed. Retina. 3rd ed. St. Louis, MO: Mosby; 2001:113.
17. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;240: 1546-1548.
18. Hui DY. A no-no for NonO and JNK in extracellular matrix homeostasis and vascular stability. Arterioscler Thromb Vasc Biol 2007;27:1677-1678.
19. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703.
20. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009;147:825-830.